Effects of Stigmasterol and β-Sitosterol on Nonalcoholic Fatty Liver Disease in a Mouse Model: A Lipidomic Analysis

被引:83
|
作者
Feng, Simin [1 ,2 ,3 ]
Gan, Ling [1 ]
Yang, Chung S. [2 ]
Liu, Anna B. [2 ]
Lu, Wenyun [5 ,6 ]
Shao, Ping [1 ]
Dai, Zhuqing [4 ]
Sun, Peilong [1 ]
Luo, Zisheng [3 ]
机构
[1] Zhejiang Univ Technol, Dept Food Sci & Technol, Hangzhou 310014, Zhejiang, Peoples R China
[2] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Chem Biol, Piscataway, NJ 08854 USA
[3] Zhejiang Univ, Coll Biosyst Engn & Food Sci, Key Lab Agroprod Postharvest Handling, Zhejiang Key Lab Agrifood Proc,Minist Agr, Hangzhou 310058, Zhejiang, Peoples R China
[4] Jiangsu Acad Agr Sci, Inst Agroprod Proc, Nanjing 210014, Jiangsu, Peoples R China
[5] Princeton Univ, Dept Chem, Princeton, NJ 08544 USA
[6] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA
基金
美国国家卫生研究院; 中国博士后科学基金;
关键词
stigmasterol; beta-sitosterol; fatty liver; mice; cholesterol; lipidomics; SACCHARUM-OFFICINARUM L; WESTERN-STYLE DIET; OXIDATIVE STRESS; PLANT STEROLS; HEPATIC INFLAMMATION; LOWERING PROPERTIES; METABOLIC SYNDROME; CHOLESTEROL; MICE; PHYTOSTEROLS;
D O I
10.1021/acs.jafc.7b06146
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
To study the effects of stigmasterol and beta-sitosterol on high-fat Western diet (HFWD)-induced nonalcoholic fatty liver disease (NAFLD), lipidomic analyses were conducted in liver samples collected after 33 weeks of the treatment. Principal component analysis showed these phytosterols were effective in protecting against HFWD-induced NAFLD. Orthogonal projections to latent structures-discriminate analysis (OPLS-DA) and S-plots showed that triacylglycerols (TGs), phosphatidylcholines, cholesteryl esters, diacylglycerols, and free fatty acids (FFAs) were the major lipid species contributing to these discriminations. The alleviation of NAFLD is mainly associated with decreases in hepatic cholesterol, TGs with polyunsaturated fatty acids, and alterations of free hepatic FFA. In condusion, phytosterols, at a dose comparable to that suggested for humans by the FDA for the reduction of plasma cholesterol levels, are shown to protect against NAFLD in this long-term (33-week) study.
引用
收藏
页码:3417 / 3425
页数:9
相关论文
共 50 条
  • [41] Nonalcoholic Fatty Liver Disease
    Sweet, Patrick H.
    Khoo, Teresa
    Nguyen, Steven
    [J]. PRIMARY CARE, 2017, 44 (04): : 599 - +
  • [42] Nonalcoholic Fatty Liver Disease
    Wang, Xiao Jing
    Malhi, Harmeet
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 169 (09) : ITC65 - ITC80
  • [43] Nonalcoholic Fatty Liver Disease
    Fitzgerald, Margaret A.
    [J]. NURSE PRACTITIONER, 2007, 32 (02): : 6 - 7
  • [44] Nonalcoholic fatty liver disease
    Elizabeth M. Brunt
    Vincent W.-S. Wong
    Valerio Nobili
    Christopher P. Day
    Silvia Sookoian
    Jacquelyn J. Maher
    Elisabetta Bugianesi
    Claude B. Sirlin
    Brent A. Neuschwander-Tetri
    Mary E. Rinella
    [J]. Nature Reviews Disease Primers, 1
  • [45] Nonalcoholic fatty liver disease
    Madan, P
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (07) : 734 - 735
  • [46] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [47] Nonalcoholic Fatty Liver Disease
    Filipovic, Branka
    Forbes, Alastair
    Tepes, Bojan
    Dumitrascu, Dan L.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 2018
  • [48] Nonalcoholic fatty liver disease
    Bebawi, Emmanuel
    Takla, Mark
    Leonard, Jennifer
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (26) : E909 - E909
  • [49] Nonalcoholic fatty liver disease
    Lemoine, Maud
    Serfaty, Lawrence
    [J]. PRESSE MEDICALE, 2012, 41 (02): : 169 - 189
  • [50] Nonalcoholic Fatty Liver Disease
    Worm, N.
    Stein, J.
    Strohle, A.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2016, 25 (02): : 85 - 94